Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Molecular Partners Ag (MOLN) Current Deferred Revenue (2020 - 2024)

Historic Current Deferred Revenue for Molecular Partners Ag (MOLN) over the last 5 years, with Q2 2024 value amounting to $646889.2.

  • Molecular Partners Ag's Current Deferred Revenue fell 9003.69% to $646889.2 in Q2 2024 from the same period last year, while for Jun 2024 it was $646889.2, marking a year-over-year decrease of 9003.69%. This contributed to the annual value of $4.9 million for FY2023, which is 2657.36% down from last year.
  • Molecular Partners Ag's Current Deferred Revenue amounted to $646889.2 in Q2 2024, which was down 9003.69% from $2183.7 recorded in Q1 2024.
  • Molecular Partners Ag's Current Deferred Revenue's 5-year high stood at $30.7 million during Q4 2021, with a 5-year trough of $2183.7 in Q1 2024.
  • For the 5-year period, Molecular Partners Ag's Current Deferred Revenue averaged around $5.5 million, with its median value being $2.8 million (2023).
  • In the last 5 years, Molecular Partners Ag's Current Deferred Revenue surged by 29653.97% in 2021 and then plummeted by 9003.69% in 2024.
  • Over the past 5 years, Molecular Partners Ag's Current Deferred Revenue (Quarter) stood at $7.7 million in 2020, then surged by 296.54% to $30.7 million in 2021, then tumbled by 78.33% to $6.7 million in 2022, then dropped by 26.57% to $4.9 million in 2023, then plummeted by 86.76% to $646889.2 in 2024.
  • Its Current Deferred Revenue was $646889.2 in Q2 2024, compared to $2183.7 in Q1 2024 and $4.9 million in Q4 2023.